6-K

OBSEVA SA

Date: January 3, 2018

/s/ Tim Adams

Chief Financial Officer

0001193125-18-001057.txt : 20180103 0001193125-18-001057.hdr.sgml : 20180103 20180103080033 ACCESSION NUMBER: 0001193125-18-001057 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180103 FILED AS OF DATE: 20180103 DATE AS OF CHANGE: 20180103 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ObsEva SA CENTRAL INDEX KEY: 0001685316 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: V8 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37993 FILM NUMBER: 18503353 BUSINESS ADDRESS: STREET 1: CHEMIN DES AULX, 12 CITY: PLAN-LES-OUATES STATE: V8 ZIP: 1228 BUSINESS PHONE: 0041-0-22-552-1558 MAIL ADDRESS: STREET 1: CHEMIN DES AULX, 12 CITY: PLAN-LES-OUATES STATE: V8 ZIP: 1228 6-K 1 d516572d6k.htm 6-K 6-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the Month of January 2018

Commission File Number: 001-37993

OBSEVA SA

(Translation of registrant’s name into English)

Chemin des Aulx, 12

1228 Plan-les-Ouates

Geneva, Switzerland

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

☒ Form 20-F ☐ Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

EXPLANATORY NOTE

ObsEva SA, a clinical stage Women’s Health company announced today that Dr. Ernest Loumaye, co-founder and CEO of ObsEva (the “Company”), has begun a personal leave of absence for medical reasons. Dr. Loumaye is expected to spend the next several weeks recuperating. Dr. Loumaye will continue to be the Chief Executive Officer during his absence.

The Board of Directors of the Company has created an Office of the CEO consisting of Dr. Frank Verwiel, the Company’s Chairperson of the Board of Directors, Dr. Jean-Pierre Gotteland, the Company’s Chief Scientific Officer, and Tim Adams, the Company’s Chief Financial Officer. In Dr. Loumaye’s absence, the Office of the CEO will be responsible for overseeing the operations of the Company on a day to day basis.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.